Riskpilot← Back to searchSign inGet full accessIMMUNOCORP CONSUMER HEALTH AS
ASActiveOrg 981633482Philip Pedersens Vei 20, 1366 LysakerWholesale of other food · NACE 4638Est. 20000 employeeswww.nbg247.no
Revenue 2024
NOK 0
EBITDA margin
—
+33% vs 2023
Equity ratio
97.0%
Financial strength
Net profit 2024
NOK 644K
-49% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -97K | +33% |
| Net profit | NOK 644K | -49% |
| Total assets | NOK 4,1M | +12% |
| Equity | NOK 4M | +19% |
| Employees | 0 | — |
Legal name
IMMUNOCORP CONSUMER HEALTH AS
Org number
981633482
Legal form
Aksjeselskap
NACE code
4638 · Wholesale of other food
Founded
10. mars 2000
Share capital
NOK 1 000 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Markedsføre og selge vitenskapelig dokumenterte kosttilskudd, og dermed tilknyttet virksomhet.
Address
Philip Pedersens Vei 20, 1366 Lysaker
Website
www.nbg247.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −50 | −72 | 88 | −145 | −97 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −50 | −72 | 88 | −145 | −97 |
| Net financials | −116 | 942 | 775 | 1 488 | 853 |
| Profit before tax | −166 | 870 | 863 | 1 343 | 756 |
| Tax | −93 | 33 | −0 | 74 | 112 |
| Net profit | −74 | 837 | 863 | 1 269 | 644 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 431 | 2 296 | 3 036 | 3 672 | 4 095 |
| Equity | 1 426 | 2 145 | 3 008 | 3 327 | 3 971 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 5 | 152 | 28 | 346 | 125 |
| Total debt | 5 | 152 | 28 | 346 | 125 |
EBITDA margin
-9705200.0%
This company
15.8%
Market median
-61425416% vs market
20202024
Equity ratio
97.0%
This company
38.2%
Market median
+154% vs market
20202024
Return on equity
16.2%
This company
18.4%
Market median
+12% vs market
20202024
Net profit margin
64397500.0%
This company
8.1%
Market median
+795030764% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
MB Deputy Member | Deputy Member | 2012 |
KF Chief Executive Officer | Chief Executive Officer | 2010 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2012 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 | |
| Company | 50% | 50% | 2024 | |
| Company | 50% | 50% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Telecom As
IMMUNOCORP CONSUMER HEALTH AS Board members of IMMUNOCORP CONSUMER HEALTH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Brennesvik-Jensen | Deputy Member | 0 companies |
| Kenneth Frode Goovaerts Bern | Chief Executive Officer | 0 companies |
| Andres Kongsgaard Flaaten | Chairman | 0 companies |